secwatch.observer — SEC 8-K summary
======================================

Issuer:     DEXCOM INC (DXCM)
CIK:        0001093557
Form:       8-K
Filed at:   2023-02-09T23:59:59+00:00
Accession:  0001093557-23-000022
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dexcom Q4 revenue $815.2M (+17% YoY); G7 CGM FDA cleared; guides 2023 rev $3.35-3.49B
--------------------------------------------------------------------------------

- Q4 2022 revenue $815.2M (+17% reported, +20% organic); U.S. +17%, international +15% (organic +27%).
- GAAP operating income $125.4M (15.4% margin) vs $0.6M in Q4 2021; non-GAAP operating income $172.1M (21.1% margin).
- GAAP EPS $0.22 diluted; non-GAAP EPS $0.34 diluted; cash & marketable securities $2.46B.
- FDA cleared Dexcom G7 CGM for ages 2+; rollout in U.S. market in 2023.
- FY2023 guidance: revenue $3.35-3.49B (15-20% growth); non-GAAP gross margin 62-63%; non-GAAP op margin ~16.5%; Adj. EBITDA margin ~26%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1093557/000109355723000022/0001093557-23-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1093557/000109355723000022/dxcm-20230209.htm
  HTML page:      https://secwatch.observer/filing/0001093557-23-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer